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Current guidelines advocate the use of screeningendoscopy in patients with cirrhosis to identifythose who could benefit from prophylactic ther-
apy to decrease the incidence of initial variceal hemor-
rhage.1,2 The decision analysis performed by Spiegel et al.
reported in this issue of HEPATOLOGY challenges this
practice and illustrates the potential benefit of empiric
-blockers for all patients with compensated cirrhosis.
Based on available literature, one must now decide
whether these data should immediately affect clinical
practice. The purpose of this editorial is to evaluate this
study from an evidence-based perspective, identify key
components that affect the results, and highlight unre-
solved issues that require further investigation.
Variceal bleeding is a major cause of mortality in pa-
tients with cirrhosis.3 At the initial time of presentation
with cirrhosis, about 30% of patients with compensated
disease and 60% of those with decompensated disease
have esophageal varices.4 The annual risk of developing de
novo varices after presentation appears to be around 8%.5
In patients with known varices, but who have never expe-
rienced variceal hemorrhage, the annual risk of bleeding is
between 2% and 70%, depending on the size of the vari-
ces, severity of liver disease, and endoscopic criteria.6 His-
torically, the 1-month mortality rate associated with
variceal hemorrhage has been as high as 50%; even with
the advent of endoscopic therapy and the improvement in
critical care, the mortality rate appears to be around
20%.7,8 Given the high prevalence of varices, the high risk
of initial hemorrhage from esophageal varices, and the
high mortality rate from hemorrhage, primary prophy-
laxis is an attractive strategy.
Randomized controlled trials evaluating primary pro-
phylaxis with nonselective -blockers have been pub-
lished. Based on results from these trials, 3 well-designed
meta-analyses have been performed, all showing the effi-
cacy of -blockers in reducing the risk of a first variceal
hemorrhage by about 50%; additionally, all showed a
trend toward improved survival.4,5,9 As a result, the Amer-
ican College of Gastroenterology and the American Asso-
ciation for the Study of Liver Disease have recommended
screening endoscopy every 2 years in patients with cirrho-
sis, followed by pharmacologic prophylaxis in patients
with large varices.1,2 More recently, randomized con-
trolled trials evaluating prophylactic endoscopic band li-
gation of esophageal varices have been performed. A
meta-analysis showed a relative risk of variceal hemor-
rhage with band ligation compared with no therapy of
0.36 (95% CI, 0.26-0.50) and a relative risk for all-cause
mortality of 0.55 (0.43-0.71).10 In the same meta-analy-
sis, 4 studies comparing band ligation with -blockers
had a pooled relative risk of bleeding with band ligation of
0.48 (0.24-0.96), but no difference in mortality. This
raises the issue of whether the decreased risk of bleeding is
worth the cost of multiple endoscopies, without benefit in
survival. In such cases, decision analysis is an ideal study
design to examine the issue.
The field of quantitative analysis has at its disposal a
variety of tools designed to assess competing strategies
under conditions of uncertainty. Cost-effectiveness anal-
ysis is a subset of decision analysis that compares resource
use and benefit derived from different strategies under
conditions of limited resources.11-19 Quantitative analyses
evaluating interventions to prevent initial variceal hem-
orrhage in patients with cirrhosis have previously been
published. The first compared propranolol with sclero-
therapy, but did not consider variceal band ligation.20
This study assumed that 15% of participants would dis-
continue therapy due to adverse effects, but otherwise
assumed perfect patient adherence. A second published
study did not perform a formal cost-effectiveness analysis
and only considered high rates of adherence to therapy.21
Furthermore, both studies assumed that varices had al-
ready been documented by endoscopy; thus, neither ex-
amined the issue regarding initiation of screening.
More recently, Arguedas et al. created a Markov pro-
cess to compare strategies of observation, empiric
-blocker without screening endoscopy, screening fol-
lowed by -blocker for appropriate patients, and screen-
ing followed by band ligation over a 5-year time
horizon.22 They assumed a 15% rate of intolerance of
medications, but otherwise did not account for nonadher-
ence to therapy. The study concluded that the preferred
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strategy depended on the severity of liver disease. In
Child-Pugh class A patients, the most cost-effective strat-
egy was endoscopic screening followed by -blocker; in
Child-Pugh class B or C, empiric -blocker was both the
most effective and most cost-effective strategy. In a sensi-
tivity analysis, the investigators determined that impor-
tant variables included the prevalence of varices, the rate
of development or progression of varices, the rate of in-
tolerance to -blockers, and the effectiveness and cost of
medications and band ligation.
The study reported by Spiegel et al. adds significant
insight to the issues regarding primary prophylaxis of
variceal hemorrhage. This work fulfills all requirements of
a well-performed cost-effectiveness analysis. Using a
3-year time horizon and the perspective of a third party
insurer (the Health Care Finance Administration,
HCFA), they modeled a population of patients with
Child’s class A or B cirrhosis who were assumed to have no
contraindication to the use of propranolol or previous
investigation for varices. Briefly, they examined strategies
including no prophylaxis, empiric propranolol for all sub-
jects, screening upper endoscopy followed by propranolol
if moderate or large varices were diagnosed, screening fol-
lowed by band ligation if moderate or large varices were
diagnosed, selective screening of high-risk patients fol-
lowed by propranolol, or selective screening followed by
band ligation. The investigators accounted for intolerance
to propranolol, as well as for nonadherence to therapy.
The primary outcome of the analysis was the incremental
cost-effectiveness ratio, in this case the difference in costs
divided by the difference in the number of initial variceal
bleeds between competing strategies.
A few methodologic caveats may be noted: discounting
of costs and benefits are usually performed in analyses
longer than 1 year, and the time frame examined in this
study, although understandably limited by available liter-
ature to provide variable inputs, may not be adequate to
fully assess the impact of these strategies on patients with
compensated cirrhosis whose lifespan may be longer than
the period of time modeled. Additionally, the primary
end point of the analysis is limited to the reduction in the
incidence of initial variceal hemorrhage. The analysis does
not examine overall mortality, or patient preference for
different health states (utility). As a result, mortality and
morbidity associated with interventions incur cost, but no
decrement in overall outcome. Note that this is not
merely a hypothetical problem, but a real one that has
been realized in previous clinical trials such as one study
reported by Angelico et al. in which, although the inci-
dence of variceal hemorrhage rates was reduced, overall
mortality was higher in one intervention group.23
The investigators concluded that the incremental cost-
effectiveness ratio of empiric propranolol for all subjects
compared with observation was $12,408 per initial
variceal hemorrhage prevented. They calculated that en-
doscopic screening for varices was prohibitively expen-
sive, regardless of whether propranolol or band ligation
was used for prophylaxis. The incremental cost-effective-
ness ratios for screening followed by propranolol and
screening followed by band ligation were $175,873 and
$178,400 per initial bleed prevented, respectively, com-
pared with empiric propranolol. Likewise, they found
that strategies of selective screening of high-risk sub-
groups of cirrhotic patients were not cost effective, be-
cause these strategies were associated with only marginal
decrements in cost, but large losses in effectiveness com-
pared with nonselective screening. In fact, selective
screening was dominated by the strategy of empiric pro-
pranolol, meaning that empiric propranolol was both less
costly and more effective than selective screening.
The conclusions of the analysis were dependent on
several assumptions that were identified in a series of sen-
sitivity analyses. These factors included the effectiveness
of therapy to decrease the incidence of variceal hemor-
rhage, compliance (or adherence) to medical therapy, and
the cost of therapy. One factor not varied by the investi-
gators was the assumption that patients informed of the
presence of varices at risk for bleeding by endoscopy
would be more compliant with therapy than those in
whom empiric therapy was undertaken. This assumption
explains the curious result that reserving therapy for only
those diagnosed with at-risk varices was more effective at
decreasing the risk of initial variceal hemorrhage than
empiric -blocker therapy for all patients with compen-
sated cirrhosis. Although reversal of this assumption
would alter the results, it would do so by worsening the
incremental cost effectiveness of endoscopic screening to
detect varices, thus strengthening the argument of the
investigators.
Comparison of the studies by Arguedas et al.22 and
Spiegel et al. reveals additional insight into the issue of
primary prophylaxis for variceal bleeding. Spiegel et al.
found that in patients with compensated cirrhosis, em-
piric primary prophylaxis with -blocker was the most
cost-effective strategy to prevent variceal hemorrhage. En-
doscopic screening followed by either -blockers or band
ligation prevented a greater number of initial bleeds, but
at a prohibitive cost. Arguedas et al. also found that em-
piric -blockers constituted the most cost-effective strat-
egy, but only in patients with decompensated cirrhosis;
those with compensated disease were most efficiently
managed by screening endoscopy with prophylaxis for
patients with varices. The discrepancy between studies is
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likely based on different assumptions for the model vari-
ables. Arguedas et al. assumed a relative risk of variceal
hemorrhage with band ligation compared with no ther-
apy of 0.55, derived from individual randomized con-
trolled trials, whereas Spiegel et al. assumed a relative risk
of 0.36 based on a published meta-analysis.10 In fact, the
base-case value of the effectiveness of band ligation in the
Arguedas model was outside of the 95% confidence inter-
val reported by that meta-analysis. With the range of vari-
able assumptions used in the sensitivity analysis, Arguedas
et al. reported that band ligation would be the preferred
strategy only if the relative risk of hemorrhage was less
than 0.3. Finally, the Arguedas model assumed perfect
adherence to medical therapy, whereas Spiegel’s ac-
counted for nonadherence, which likely resulted in band
ligation becoming the most effective strategy.
Despite the fact that these studies have discrepancies in
the relative cost and effectiveness of prophylactic strate-
gies, they retain general agreement regarding the viability
of a strategy of empiric -blocker without screening. Ar-
guedas et al. concluded that the scenarios in which screen-
ing would prevent a greater number of variceal bleeds
would require the prevalence of large varices to be low
(less than 10%) or the rate of development or progres-
sion of varices to be relatively slow (less than 8% per year);
otherwise, variceal hemorrhage occurring in the interval
between screenings appeared to hamper the effectiveness
of endoscopic screening. Paradoxically, Spiegel et al.
found that selectively screening patients at high risk for
varices was both more costly and less effective than em-
piric prophylaxis. The analysis showed that ability to pre-
dict who is at risk for varices based on clinical parameters
is too inaccurate to be incorporated into management
practice.
Quantitative analytic studies such as these cost-effec-
tiveness analyses may be hypothesis generating, in that
variables critical to the understanding of disease manage-
ment can be identified and clinical research may be di-
rected to pursue questions of particular relevance. In the
case of primary prophylaxis of variceal hemorrhage, the
important variables determining the preferred strategy in-
clude the prevalence of large varices, the relative effective-
ness of -blockers and band ligation, the costs of each,
and the rate of adherence to medical therapy. The base-
case assumptions made by Spiegel et al. regarding these
variables were derived from the best available data; how-
ever, the conclusions were sensitive to key variables within
the range reported in the literature. Importantly, the in-
vestigators have shown the viability of a strategy of em-
piric pharmacologic prophylaxis without screening.
Whether empiric prophylaxis is more cost effective than
screening followed by medical therapy or band ligation
remains unresolved. The answer depends heavily on the
real-life adherence rates to -blockers by patients with
cirrhosis and on the quality of life associated with
-blockers.
Although it may be premature to adopt the use of
empiric prophylactic -blocker therapy for patients with
either compensated or decompensated cirrhosis, this anal-
ysis calls for a prospective study comparing empiric versus
screening-directed prophylaxis. Additionally, since the
downside of -blockers is not cost, but side effects and
patient adherence, it is further suggested that the trial
incorporate a measure of effectiveness as well as efficacy.
By this it is meant that the population studied in such a
trial should not be limited to subjects fulfilling strict in-
clusion or exclusion criteria, but rather be representative
of the population to which the results may be more
broadly applied. Truly, decision analysis may not be able
to tell you what to do, but rather what to think about.
JOEL H. RUBENSTEIN, M.D.
JOHN M. INADOMI, M.D.
VA Center for Practice Management and Outcomes
Research and The Division of Gastroenterology
Department of Medicine
University of Michigan Medical Center
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